Axsome Therapeutics reports Q3 EPS (94c), consensus (90c)

Reports Q3 revenue $170.992M, consensus $162.99M. “Axsome posted strong revenue growth in the third quarter driven by contributions from all three of our marketed products,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics (AXSM). “Our broad development pipeline continues to advance, and we recently submitted our supplemental NDA for AXS-05 for the treatment of Alzheimer’s disease agitation, a serious condition affecting millions of patients in the U.S., and a critical unmet medical need. With robust commercial performance and pipeline execution, Axsome is well positioned to continue delivering substantial and sustained growth and transformative new medicines for patients living with serious CNS disorders.”